MiR-218 suppresses cardiac myxoma proliferation by targeting myocyte enhancer factor 2D

Oncology Reports

Volumn 33, Issue 5, 2015, Pages 2606-2612

  Cao, Quanxing ^a   Dong, Pingshuan ^a   Wang, Yanyu ^a   Zhang, Junwei ^a   Shi, Xinge ^a   Wang, Yongsheng ^a  

^a HENAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

MEF2D; Mir 218; Myxoma

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45A; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45B; MICRORNA; MICRORNA 218; MYOCYTE ENHANCER FACTOR 2; MYOCYTE ENHANCER FACTOR 2A; MYOCYTE ENHANCER FACTOR 2C; MYOCYTE ENHANCER FACTOR 2D; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; MESSENGER RNA; MIRN218 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENICITY; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE CONTROL; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE REPRESSION; GROWTH INHIBITION; HEART MYXOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RNA INTERFERENCE; TUMOR CELL; TUMOR GROWTH; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; CELL CYCLE; GENETICS; HEART TUMOR; METABOLISM; MUSCLE CELL; MYXOMA; NUDE MOUSE; PATHOLOGY;

3' UNTRANSLATED REGIONS; ANIMALS; CELL CYCLE; CELL PROLIFERATION; CELLS, CULTURED; DOWN-REGULATION; HEART NEOPLASMS; HUMANS; MEF2 TRANSCRIPTION FACTORS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; MUSCLE CELLS; MYXOMA; RNA, MESSENGER;

EID: 84927134164     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3861     Document Type: Article

References (19)

1. Tatli S and Lipton MJ: CT for intracardiac thrombi and tumors. Int J Cardiovasc Imaging 21:115-131, 2005.
2. Rubin P, Williams JP, Devesa SS, Travis LB and Constine LS: Cancer genesis across the age spectrum: Associations with tissue development, maintenance, and senescence. Semin Radiat Oncol 20:3-11, 2010.
3. Rana MS, Christoffels VM and Moorman AF: A molecular and genetic outline of cardiac morphogenesis. Acta Physiol 207:588-615, 2013.
4. Edmondson DG, Lyons GE, Martin JF and Olson EN: Mef2 gene expression marks the cardiac and skeletal muscle lineages during mouse embryogenesis. Development 120:1251-1263, 1994.
5. Lin Q, Schwarz J, Bucana C and Olson EN: Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C. Science 276:1404-1407, 1997.
6. Guo Y, Kühl SJ, Pfister AS, Cizelsky W, Denk S, Beer-Molz L and Kühl M: Comparative analysis reveals distinct and overlapping functions of Mef2c and Mef2d during cardiogenesis in Xenopus laevis. PLoS One 9:e87294, 2014.
7. Prima V, Gore L, Caires A, Boomer T, Yoshinari M, Imaizumi M, Varella-Garcia M and Hunger SP: Cloning and functional characterization of MEF2D/DAZAP1 and DAZAP1/MEF2D fusion proteins created by a variant t (1;19) (q23;p13.3) in acute lymphoblastic leukemia. Leukemia 19:806-813, 2005.
8. Prima V and Hunger SP: Cooperative transformation by MEF2D/DAZAP1 and DAZAP1/MEF2D fusion proteins generated by the variant t (1;19) in acute lymphoblastic leukemia. Leukemia 21:2470-2475, 2007.
9. 2-M transition genes. Cancer Res 74:1452-1462, 2014.
10. Kim Y, Phan D, Van Rooij E, Wang DZ, McAnally J, Qi X, Richardson JA, Hill JA, Bassel-Duby R and Olson EN: The MEF2D transcription factor mediates stress-dependent cardiac remodeling in mice. J Clin Invest 118:124-132, 2008.
11. Geng J, Zhao Z, Kang W, Wang W, Zhang Y and Zhiming GE: Atorvastatin reverses cardiac remodeling possibly through regulation of protein kinase D/myocyte enhancer factor 2D activation in spontaneously hypertensive rats. Pharmacol Res 61:40-47, 2010.
12. Negishi M, Sakamoto H, Sakamaki T, Ishikawa O, Kanda T, Tamura J, Kurabayashi M and Nagai R: Disaccharide analysis of glycosaminoglycans synthesized by cardiac myxoma cells in tumor tissues and in cell culture. Life Sci 73:849-856, 2003.
13. Sauls K, De Vlaming A, Harris BS, et al: Developmental basis for filamin-A-associated myxomatous mitral valve disease. Cardiovasc Res 96:109-119, 2012.
14. Mantovani G, Bondioni S, Corbetta S, et al: Analysis of GNAS1 and PRKAR1A gene mutations in human cardiac myxomas not associated with multiple endocrine disorders. J Endocrinol Invest 32:501-504, 2009.
15. Yin Z, Jones GN, Towns WH II, Zhang X, Abel ED, Binkley PF, Jarjoura D and Kirschner LS: Heart-specific ablation of Prkar1a causes failure of heart development and myxomagenesis. Circulation 117:1414-1422, 2008.
16. Gao X and Jin W: The emerging role of tumor-suppressive microRNA-218 in targeting glioblastoma stemness. Cancer Lett 353:25-31, 2014.
17. Wei Y, Du Y, Chen X, Li P, Wang Y, Zang W, Zhao L, Li Z and Zhao G: Expression patterns of microRNA-218 and its potential functions by targeting CIP2A and BMI1 genes in melanoma. Tumour Biol 35:8007-8015, 2014.
18. Zhang C, Ge S, Hu C, Yang N and Zhang J: miRNA-218, a new regulator of HMGB1, suppresses cell migration and invasion in non-small cell lung cancer. Acta Biochim Biophys Sin 45:1055.1061, 2013.
19. Vetere G, Barbato C, Pezzola S, Frisone P, Aceti M, Ciotti M, Cogoni C, Ammassari-Teule M and Ruberti F: Selective inhibition of miR-92 in hippocampal neurons alters contextual fear memory. Hippocampus 24:1458-1465, 2014.